Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
All content for Talk Radioisotopes: Going Nuclear on Cancer is the property of Nusano and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
Jeff Jones, Managing Director, Senior Analyst at Oppenheimer & Company
Talk Radioisotopes: Going Nuclear on Cancer
36 minutes 37 seconds
9 months ago
Jeff Jones, Managing Director, Senior Analyst at Oppenheimer & Company
On our first episode of ‘Talk Radioisotopes: Going Nuclear on Cancer,' host Scott Larrivee is joined by co-host Dr. Sarah Scouten and guest Jeff Jones of Oppenheimer & Company
Talk Radioisotopes: Going Nuclear on Cancer
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
